Canaccord Genuity Assumes LSI Industries at Buy, Announces Price Target of $9
Canaccord Genuity analyst George Gianarikas assumes LSI Industries (NASDAQ:LYTS) with a Buy rating and announces Price Target of $9.
Cantor Fitzgerald Initiates Coverage On Zscaler with Neutral Rating, Announces Price Target of $160
Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on Zscaler (NASDAQ:ZS) with a Neutral rating and announces Price Target of $160.
UBS Initiates Coverage On Bloomin Brands with Neutral Rating, Announces Price Target of $23
UBS analyst Dennis Geiger initiates coverage on Bloomin Brands (NASDAQ:BLMN) with a Neutral rating and announces Price Target of $23.
Barclays Initiates Coverage On CCC Intelligent Solutions with Equal-Weight Rating, Announces Price Target of $10
Barclays analyst Saket Kalia initiates coverage on CCC Intelligent Solutions (NYSE:CCCS) with a Equal-Weight rating and announces Price Target of $10.
Cantor Fitzgerald Initiates Coverage On Cerberus Cyber Sentinel with Overweight Rating, Announces Price Target of $5
Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on Cerberus Cyber Sentinel (NASDAQ:CISO) with a Overweight rating and announces Price Target of $5.
Goldman Sachs Initiates Coverage On Vertex with Buy Rating, Announces Price Target of $20
Goldman Sachs analyst Adam Hotchkiss initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and announces Price Target of $20.
Goldman Sachs Initiates Coverage On Zuora with Neutral Rating, Announces Price Target of $9
Goldman Sachs analyst Adam Hotchkiss initiates coverage on Zuora (NYSE:ZUO) with a Neutral rating and announces Price Target of $9.
Jefferies Assumes Amphastar Pharmaceuticals at Buy, Announces Price Target of $36
Jefferies analyst Glen Santangelo assumes Amphastar Pharmaceuticals (NASDAQ:AMPH) with a Buy rating and announces Price Target of $36.
Jefferies Initiates Coverage On Viatris with Hold Rating, Announces Price Target of $11
Jefferies analyst Glen Santangelo initiates coverage on Viatris (NASDAQ:VTRS) with a Hold rating and announces Price Target of $11.
Oppenheimer Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $30
Oppenheimer analyst Jay Olson initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and announces Price Target of $30.